4D Molecular Therapeutics (NASDAQ:FDMT) Insider David Kirn Sells 1,922 Shares of Stock

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) insider David Kirn sold 1,922 shares of the company’s stock in a transaction on Monday, June 1st. The stock was sold at an average price of $10.02, for a total transaction of $19,258.44. Following the transaction, the insider owned 1,057,231 shares of the company’s stock, valued at $10,593,454.62. This trade represents a 0.18% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

4D Molecular Therapeutics Stock Performance

Shares of NASDAQ:FDMT opened at $9.27 on Wednesday. The company has a fifty day moving average of $9.53 and a 200-day moving average of $9.28. The company has a market capitalization of $484.64 million, a PE ratio of -3.61 and a beta of 2.75. 4D Molecular Therapeutics, Inc. has a 52-week low of $3.68 and a 52-week high of $12.34.

4D Molecular Therapeutics (NASDAQ:FDMT) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($1.01) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.97) by ($0.04). The company had revenue of $3.05 million for the quarter, compared to analyst estimates of $2.59 million. 4D Molecular Therapeutics had a negative return on equity of 36.83% and a negative net margin of 182.34%. On average, equities analysts forecast that 4D Molecular Therapeutics, Inc. will post -3.74 EPS for the current fiscal year.

Wall Street Analyst Weigh In

FDMT has been the subject of several research analyst reports. Jefferies Financial Group reiterated a “buy” rating and set a $21.00 price target (down from $40.00) on shares of 4D Molecular Therapeutics in a report on Monday, March 30th. Royal Bank Of Canada upped their price target on shares of 4D Molecular Therapeutics from $32.00 to $35.00 and gave the stock an “outperform” rating in a report on Thursday, March 19th. Wall Street Zen downgraded shares of 4D Molecular Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Chardan Capital restated a “buy” rating and issued a $26.00 price objective on shares of 4D Molecular Therapeutics in a report on Thursday, March 19th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a report on Monday, April 20th. Seven research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, 4D Molecular Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $29.88.

Institutional Trading of 4D Molecular Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of FDMT. AQR Capital Management LLC acquired a new stake in 4D Molecular Therapeutics in the first quarter valued at $46,000. Millennium Management LLC increased its holdings in 4D Molecular Therapeutics by 15.0% in the first quarter. Millennium Management LLC now owns 1,633,987 shares of the company’s stock valued at $5,278,000 after purchasing an additional 213,264 shares during the period. Dynamic Technology Lab Private Ltd acquired a new stake in 4D Molecular Therapeutics in the first quarter valued at $39,000. American Century Companies Inc. increased its holdings in 4D Molecular Therapeutics by 11.5% in the second quarter. American Century Companies Inc. now owns 48,810 shares of the company’s stock valued at $181,000 after purchasing an additional 5,026 shares during the period. Finally, Russell Investments Group Ltd. increased its holdings in 4D Molecular Therapeutics by 11.7% in the second quarter. Russell Investments Group Ltd. now owns 21,816 shares of the company’s stock valued at $81,000 after purchasing an additional 2,284 shares during the period. 99.27% of the stock is currently owned by institutional investors and hedge funds.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.